DOCSLIB.ORG

Advisory Committee Industry Briefing Document Testosterone Replacement Therapy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Testosterone Replacement Therapy Advisory Committee Briefing Document Advisory Committee Industry Briefing Document Testosterone Replacement Therapy Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee Meeting on September 17, 2014 Advisory Committee Briefing Materials: Available for Public Release Testosterone Replacement Therapy Advisory Committee Briefing Document Table of Contents 1.0 Executive Summary.................................................................8 2.0 Testosterone Replacement Therapy: Regulatory History ....................................................................................11 2.1 Approval History in the United States .....................................................11 2.2 Requirements for Regulatory Approval...................................................12 2.3 Indication .................................................................................................13 2.4 Safety Labeling ........................................................................................14 2.5 Current Regulatory Activities..................................................................15 3.0 Testosterone, Hypogonadism, Guidelines, and Testosterone Replacement Therapy Benefits .....................16 3.1 Testosterone .............................................................................................16 3.2 Hypogonadism .........................................................................................19 3.2.1 Classification, Signs, and Symptoms of Hypogonadism.........................19 3.2.2 Prevalence of Hypogonadism ..................................................................22 3.2.3 Comorbid Conditions...............................................................................26 3.2.4 Endocrine Society Guidelines..................................................................26 3.3 Testosterone Replacement Therapy.........................................................28 3.3.1 Introduction..............................................................................................28 3.3.2 Limitations of Literature Evaluating Benefits of Testosterone Replacement Therapy ..............................................................................28 3.4 Effects of Testosterone Replacement in Hypogonadal Men....................29 3.4.1 Benefits Related to Lean Mass, Muscle Strength, and Fat Mass.............30 3.4.2 Benefits Related to Bone Mineral Density and Bone Architecture .........33 3.4.3 Benefits Related to Sexual Function........................................................36 3.4.4 Benefits Related to Fatigue......................................................................38 3.4.5 Benefits Related to Mood and Cognition.................................................40 3.4.6 Benefits Related to Special Populations ..................................................42 3.4.6.1 Metabolic Syndrome and Type 2 Diabetes Mellitus................................42 3.4.6.2 Human Immunodeficiency Virus.............................................................45 3.4.6.3 Additional Special Populations................................................................46 3.5 Limitations and Uncertainties for the Evidence of Benefit......................46 Advisory Committee Briefing Materials: Available for Public Release 1 Testosterone Replacement Therapy Advisory Committee Briefing Document 3.5.1 Late Onset Hypogonadism (Androgen Deficiency of the Aging Male) ........................................................................................................46 3.6 Ongoing Studies.......................................................................................47 3.7 Summary: Hypogonadism, Guidelines, and Benefits of Testosterone Replacement Therapy.........................................................48 4.0 Cardiovascular Risk in Hypogonadal Men.........................50 4.1 Cardiovascular Risk Introduction ............................................................50 4.2 Cardiovascular Background.....................................................................52 4.3 Incidence and Prevalence of Cardiovascular Events ...............................54 4.3.1 Cardiovascular Events in the Hypogonadal Male Population .................56 4.4 Risk Factors for Cardiovascular Events...................................................59 4.5 Associations Between Hypogonadism and Cardiovascular Events.........59 4.5.1 Type 2 Diabetes Mellitus, Obesity and Metabolic Syndrome, Hypertension, and Hyperlipidemia ..........................................................59 4.5.2 Coronary Artery Disease..........................................................................60 4.5.3 Cardiovascular and All-Cause Mortality .................................................62 4.6 Evaluation of Testosterone Replacement Therapy and Cardiovascular-Related Events................................................................65 4.6.1 Placebo-Controlled Studies......................................................................65 4.6.2 Meta-Analyses of Testosterone Replacement Therapy and Cardiovascular Events or Cardiovascular Risk Factors...........................67 4.6.2.1 Meta-Analyses of Testosterone Replacement Therapy and Cardiovascular Events .............................................................................70 4.6.2.2 Meta-Analyses of Testosterone Replacement Therapy and Cardiovascular Risk Factors ....................................................................74 4.6.3 Observational Studies ..............................................................................75 4.7 Evaluation of Testosterone Replacement Therapy and Cardiovascular Risk Factors ....................................................................84 4.8 Summary..................................................................................................90 5.0 Drug Utilization .....................................................................92 5.1 Drug Utilization Introduction ..................................................................92 5.2 Background: Prevalence of Hypogonadism and Common Comorbid Conditions...............................................................................93 5.3 Prescription Trends over Time for Testosterone Products ......................93 Advisory Committee Briefing Materials: Available for Public Release 2 Testosterone Replacement Therapy Advisory Committee Briefing Document 5.4 Prescribing Patterns by Physician Specialty............................................96 5.5 Age Distribution of Patients Receiving Testosterone Replacement Therapy ....................................................................................................98 5.6 Characteristics of Patients Receiving Testosterone Replacement Therapy ..................................................................................................100 5.7 Reported Diagnostic Codes for Patients Who Receive Testosterone Replacement Therapy.......................................................101 5.8 Presence of Testosterone Values Prior to Starting Testosterone Replacement Therapy ............................................................................103 5.9 Persistence of Testosterone Replacement Therapy Use ........................105 5.10 Summary of Utilization Data .................................................................105 6.0 Conclusions...........................................................................107 7.0 References.............................................................................110 List of Tables Table 1. FDA-Approved Branded Testosterone Products Currently Marketed in the United States..................................................................12 Table 2. Classification of Male Hypogonadism.....................................................21 Table 3. Estimation of Prevalence of Testosterone Deficiency.............................24 Table 4. Strengths and Limitations of Changes in Fat Mass, Lean Mass, and Muscle Strength ................................................................................32 Table 5. Strengths and Limitations of Changes in Bone Mineral Density.............36 Table 6. Mean ± SD Difference on Total and Domain Score of the International Index of Erectile Function (IIEF-15) Between the Testosterone and Placebo Groups............................................................37 Table 7. Strengths and Limitations of Changes in Sexual Function......................38 Table 8. Strengths and Limitations of Changes in Fatigue ....................................40 Table 9. Strengths and Limitations of Changes in Mood and Cognition...............42 Table 10. Strengths and Limitations of Improvements in Glycemic Control in Metabolic Syndrome and Type 2 Diabetes Mellitus ...........................45 Table 11. Strengths and Limitations of Testosterone Replacement Therapy in HIV-Infected Males .............................................................................46 Table 12. Annual Rates of Heart Failure per 1,000 Population in 2006..................55 Advisory Committee Briefing Materials: Available for Public Release 3 Testosterone Replacement Therapy Advisory Committee Briefing Document Table 13. Cardiovascular Events in the Hypogonadal Male Population .................57 Table 14. Summary of Studies Reporting on Low Testosterone and Coronary Artery Disease..........................................................................61
Recommended publications
  • Dehydroepiandrosterone – Is the Fountain of Youth Drying Out?

    Dehydroepiandrosterone – Is the Fountain of Youth Drying Out?

    Physiol. Res. 52: 397-407, 2003 MINIREVIEW Dehydroepiandrosterone – Is the Fountain of Youth Drying Out? P. CELEC 1,2, L. STÁRKA3 1Faculty of Medicine, 2Faculty of Natural Sciences, Comenius University, Bratislava, Slovakia and 3Institute of Endocrinology, Prague, Czech Republic Received September 15, 2002 Accepted October 7, 2002 Summary Dehydroepiandrosterone (DHEA) and its sulphate-bound form (DHEAS) are important steroids mainly of adrenal origin. Their physiological and pathophysiological functions are not yet fully identified, although a number of various possible features have been hypothesized. Most popular is the description of the “hormone of youth” as the long-term dynamics of DHEA levels are characterized by a sharp age-related decline in the late adulthood and later. Low levels of DHEA are, however, associated not only with the ageing process but also with diabetes mellitus, cardiovascular diseases and some neurological or immunological entities. In the past decade, a number of brief studies have concentrated on these relationships and also on the role of exogenous DHEA in health, disease and human well-being. This article tries to summarize some of the most important facts achieved recently. Key words Dehydroepiandrosterone • Intracrinology • Hormone replacement therapy • Steroids Introduction functions: 1) DHEA is an endogenous metabolite that cannot be patented so that pharmaceutical companies are In 1934 Butenandt and Dannenbaum isolated not interested in supporting research in this field. dehydroepiandrosterone (DHEA) from urine and in 1944 2) DHEA can be described as a “human molecule” Munson and colleagues identified its 3β-sulphate because other investigated species have much lower (DHEAS). Even now, nearly 70 years later, we still do concentrations.
  • Aspermia: a Review of Etiology and Treatment Donghua Xie1,2, Boris Klopukh1,2, Guy M Nehrenz1 and Edward Gheiler1,2*

    Aspermia: a Review of Etiology and Treatment Donghua Xie1,2, Boris Klopukh1,2, Guy M Nehrenz1 and Edward Gheiler1,2*

    ISSN: 2469-5742 Xie et al. Int Arch Urol Complic 2017, 3:023 DOI: 10.23937/2469-5742/1510023 Volume 3 | Issue 1 International Archives of Open Access Urology and Complications REVIEW ARTICLE Aspermia: A Review of Etiology and Treatment Donghua Xie1,2, Boris Klopukh1,2, Guy M Nehrenz1 and Edward Gheiler1,2* 1Nova Southeastern University, Fort Lauderdale, USA 2Urological Research Network, Hialeah, USA *Corresponding author: Edward Gheiler, MD, FACS, Urological Research Network, 2140 W. 68th Street, 200 Hialeah, FL 33016, Tel: 305-822-7227, Fax: 305-827-6333, USA, E-mail: [email protected] and obstructive aspermia. Hormonal levels may be Abstract impaired in case of spermatogenesis alteration, which is Aspermia is the complete lack of semen with ejaculation, not necessary for some cases of aspermia. In a study of which is associated with infertility. Many different causes were reported such as infection, congenital disorder, medication, 126 males with aspermia who underwent genitography retrograde ejaculation, iatrogenic aspemia, and so on. The and biopsy of the testes, a correlation was revealed main treatments based on these etiologies include anti-in- between the blood follitropine content and the degree fection, discontinuing medication, artificial inseminization, in- of spermatogenesis inhibition in testicular aspermia. tracytoplasmic sperm injection (ICSI), in vitro fertilization, and reconstructive surgery. Some outcomes were promising even Testosterone excreted in the urine and circulating in though the case number was limited in most studies. For men blood plasma is reduced by more than three times in whose infertility is linked to genetic conditions, it is very difficult cases of testicular aspermia, while the plasma estradiol to predict the potential effects on their offspring.
  • Dihydrotestosterone (Adractim®) 2.5% Gel for Topical Application

    Dihydrotestosterone (Adractim®) 2.5% Gel for Topical Application

    d g t squeezin l aa StSt gelgel Star gel from this en 0mg0m0mg 2.2.55 5mg5mg 7.7.55 10m1 mg l l 12.12.55 ge g ge ) 15m15mg f 17.17.55 ® 20m20mg g g o 22.22.55 25 25m25mg 1.25 g of g 1.25 1 1.25 1 1 1.25 g of g 1.25 27.5 30mg300mm 32.32.5.5 35m35mg drotestosterone hy 37.5 Put on a pair of gloves Gently squeeze the gel onto the mark on the ruler illustrated below – as instructed on the dispensing label. Leave for five minutes Wipe this laminated information sheet with a damp piece of kitchen paper ready for the next dose. Remove the gloves and wash them in warm soapy water ready for the next dose. of di 40m40mg © GOSH NHS Foundation Trust January 2016 © GOSH NHS Foundation Trust How is it used? Dihydrotestosterone 2.5% gel is for external It should be applied over the use only. required area of skin after washing. The gel should be left to dry for five minutes or so before putting on clothes. 1. 2. 3. Spread over the required area evenly 4. 5. Note: Dihydrotestosterone 2.5% gel should not be applied to any broken areas of skin. 42.42.55 l l 45mg45m45m ge ge 47.47.55 , ® 50mg50mm 52.52.55 55mg55mm 57.57.55 2.5 g of g 2 2.5 2 2.5 g of g 2.5 60mg600m0m 62.62.5.5 Dihydrotestosterone is a synthetic version of a hormone called testosterone.
  • Spironolactone 2021 Newborn Use Only

    Spironolactone 2021 Newborn Use Only

    Spironolactone 2021 Newborn use only Alert Spironolactone is a potassium-sparing diuretic and concomitant intake of potassium or ACE inhibitors may lead to hyperkalemia. Indication Diuretic primarily prescribed for its potassium-sparing effect. For heart failure, in conjunction with furosemide. For chronic lung disease, in conjunction with a thiazide diuretic. Bartter syndrome and Gitelman Syndrome. Action Spironolactone is a synthetic steroid that acts as a competitive aldosterone receptor antagonist, so inhibits sodium reabsorption and spares potassium. It is a weak diuretic. It also inhibits the interaction between dihydrotestosterone and the intracellular androgen receptor resulting in moderate antiandrogenic activity. Drug type Non-selective mineralocorticoid receptor antagonist. Trade name Aldactone; Spiractin Presentation Oral suspension prepared in pharmacy: 1 mg/mL; 2.5 mg/mL; 5 mg/mL. Dose 1–3 mg/kg/dose 24 hourly. Dose can be divided into different intervals. Dose adjustment Therapeutic hypothermia – Not applicable. Renal impairment – Refer to precautions section. Hepatic impairment – Refer to precautions section. Maximum dose 3 mg/kg/day Total cumulative dose Route Oral Preparation Oral suspension. Administration Administer undiluted with feeds. Monitoring Serum potassium at regular intervals. Contraindications Hyperkalaemia. Significant renal impairment. Anuria. Adrenal insufficiency. Precautions Use with caution in infants with renal or hepatic impairment. Monitor more frequently if infant is also given potassium. Drug interactions Spironolactone increases the effects of ACE inhibitors (leading to hyperkalemia), digoxin and sotalol. Adverse reactions Hyperkalaemia and metabolic acidosis. Antiandrogenic effects include reduced hirsutism and gynecomastia. There is one case report of an ovarian cyst in a neonate on spironolactone. Spironolactone interferes with 17-hydroxyprogesterone measurement, which is used to screen neonates for congenital adrenal hyperplasia.
  • Brucella Abortus Epididymo-Orchitis Relapsing in the Opposite Testis After Three Months

    Brucella Abortus Epididymo-Orchitis Relapsing in the Opposite Testis After Three Months

    ‹nfeksiyon Dergisi (Turkish Journal of Infection) 2003; 17 (1): 95-98 BRUCELLA ABORTUS EPIDIDYMO-ORCHITIS RELAPSING IN THE OPPOSITE TESTIS AFTER THREE MONTHS ÜÇ AY SONRA KARfiI TEST‹STE TEKRARLAYAN BRUCELLA ABORTUS EP‹D‹D‹MO-ORfi‹T‹ Esragül AKINCI1 Hürrem BODUR1 Çi¤dem ERBAY1 Mehmet DEVEER2 Numune Training and Research Hospital, Ankara 1 Department of Clinical Microbiology and Infectious Diseases 2 Department of Radiology Key Words: Brucellosis, Brucella abortus, orchitis, epididymitis, epididymo-orchitis, relapse Anahtar Sözcükler: Bruselloz, Brucella abortus, orflit, epididimit, epididimo-orflit, relaps SUMMARY Epididymo-orchitis caused by Brucella species is a rare infection. In this article, a 47-year-old man with relaps of Brucella abortus epididymo-orchitis in the opposite testis is presented. Testicular atrophy and aspermia occurred in the patient despite antibiotic therapy. ÖZET Brucella türlerinin neden oldu¤u epididimo-orflit ender görülen bir infeksiyondur. Bu yaz›da, karfl› testisinde tekrarlayan Brucella abortus epididimo-orflitli 47 yafl›nda bir olgu sunulmufltur. Antibiyotik tedavisine karfl›n hastada testis atrofisi ve aspermi geliflmifltir. On physical examination the left hemiscrotum was tender, INTRODUCTION hyperaemic and enlarged greatly. He had a fever of Epididymo-orchitis is a rare manifestation of brucellosis. 38.4¡ C, white blood cell count 17.000/mm3, erythrocyte Brucella species cause granulomatous orchitis usually sedimentation rate 49 mm/h, and CRP 136 mg/l (normal: presenting as an acute or chronic unilateral swelling of <5 mg/l). Urine analysis and liver function tests were the testis (1). Brucellosis is an endemic disease in Turkey. normal. No growth was detected in the ejaculate and In this case report, a patient with Brucella abortus urine cultures.
  • DHEA Sulfate, and Aging: Contribution of the Dheage Study to a Sociobiomedical Issue

    DHEA Sulfate, and Aging: Contribution of the Dheage Study to a Sociobiomedical Issue

    Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: Contribution of the DHEAge Study to a sociobiomedical issue Etienne-Emile Baulieua,b, Guy Thomasc, Sylvie Legraind, Najiba Lahloue, Marc Rogere, Brigitte Debuiref, Veronique Faucounaug, Laurence Girardh, Marie-Pierre Hervyi, Florence Latourj, Marie-Ce´ line Leaudk, Amina Mokranel, He´ le` ne Pitti-Ferrandim, Christophe Trivallef, Olivier de Lacharrie` ren, Stephanie Nouveaun, Brigitte Rakoto-Arisono, Jean-Claude Souberbiellep, Jocelyne Raisonq, Yves Le Boucr, Agathe Raynaudr, Xavier Girerdq, and Franc¸oise Foretteg,j aInstitut National de la Sante´et de la Recherche Me´dicale Unit 488 and Colle`ge de France, 94276 Le Kremlin-Biceˆtre, France; cInstitut National de la Sante´et de la Recherche Me´dicale Unit 444, Hoˆpital Saint-Antoine, 75012 Paris, France; dHoˆpital Bichat, 75877 Paris, France; eHoˆpital Saint-Vincent de Paul, 75014 Paris, France; fHoˆpital Paul Brousse, 94804 Villejuif, France; gFondation Nationale de Ge´rontologie, 75016 Paris, France; hHoˆpital Charles Foix, 94205 Ivry, France; iHoˆpital de Biceˆtre, 94275 Biceˆtre, France; jHoˆpital Broca, 75013 Paris, France; kCentre Jack-Senet, 75015 Paris, France; lHoˆpital Sainte-Perine, 75016 Paris, France; mObservatoire de l’Age, 75017 Paris, France; nL’Ore´al, 92583 Clichy, France; oInstitut de Sexologie, 75116 Paris, France; pHoˆpital Necker, 75015 Paris, France; qHoˆpital Broussais, 75014 Paris, France; and rHoˆpital Trousseau, 75012 Paris, France Contributed by Etienne-Emile Baulieu, December 23, 1999 The secretion and the blood levels of the adrenal steroid dehydro- number of consumers. Extravagant publicity based on fantasy epiandrosterone (DHEA) and its sulfate ester (DHEAS) decrease pro- (‘‘fountain of youth,’’ ‘‘miracle pill’’) or pseudoscientific asser- foundly with age, and the question is posed whether administration tion (‘‘mother hormone,’’ ‘‘antidote for aging’’) has led to of the steroid to compensate for the decline counteracts defects unfounded radical assertions, from superactivity (‘‘keep young,’’ associated with aging.
  • UPLC-MS/MS Analysis of Dihydrotestosterone, Dehydroepiandrosterone, Testosterone, Androstenedione, 17-Hydroxyprogesterone

    UPLC-MS/MS Analysis of Dihydrotestosterone, Dehydroepiandrosterone, Testosterone, Androstenedione, 17-Hydroxyprogesterone

    [ APPLICATION NOTE ] UPLC-MS/MS Analysis of Dihydrotestosterone, Dehydroepiandrosterone, Testosterone, Androstenedione, 17-Hydroxyprogesterone, and Progesterone in Serum for Clinical Research Dominic Foley and Lisa Calton Waters Corporation, Wilmslow, UK APPLICATION BENEFITS INTRODUCTION ■■ Analytical selectivity of the Steroid hormones encompass a large class of small molecules that play a central chromatographic method provides role in metabolic processes, such as regulation of sexual characteristics, blood separation of isobaric species pressure, and inflammation. Measurement of these steroids by immunoassay can be prone to analytical interference as a result of cross reactivity of ■■ UPLC-MS/MS enables high sample-throughput using reagent antibodies with structurally related steroid hormones and synthetic multi-well plate automation derivatives. UltraPerformance LC™ - tandem mass spectrometry–tandem mass spectrometry (UPLC-MS/MS) can provide analytically sensitive, ■■ Excellent agreement to EQA accurate, and precise measurement of these steroid hormones. mean values for testosterone, androstenedione, 17-OHP, Here we describe a clinical research method utilizing Oasis MAX and DHT µElution Plate technology for the extraction of Dihydrotestosterone (DHT), dehydroepiandrosterone (DHEA), testosterone, androstenedione, 17-Hydroxyprogesterone (17-OHP), and progesterone from serum, which has been automated using the Tecan Freedom EVO 100/4 liquid handler. Chromatographic separation was performed on an ACQUITY UPLC I-Class System using a CORTECS UPLC C18 Column, followed by detection on WATERS SOLUTIONS a Xevo TQ-S micro Mass Spectrometer (Figure 1). In addition, we have Oasis™ MAX µElution Plate examined External Quality Assessment (EQA) samples for testosterone, androstenedione, 17-OHP, and DHT to evaluate the bias and therefore CORTECS™ UPLC™ C18 Column suitability of the method for analyzing these steroids for clinical research.
  • A Complication of Brucellosis: Epididymoorchitis

    A Complication of Brucellosis: Epididymoorchitis

    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector International Journal of Infectious Diseases (2006) 10, 171—177 http://intl.elsevierhealth.com/journals/ijid A complication of brucellosis: Epididymoorchitis Esragu¨l Akıncı a,*,Hu¨rrem Bodur a, Mustafa Aydın C¸evik a, Ays¸e Erbay a, Selim Sırrı Eren a,I˙pek Zıraman b, Neriman Balaban c, Ali Atan d,Gu¨lu¨s¸an Ergu¨l e a Department of Infectious Diseases and Clinical Microbiology, Ankara Numune Education and Research Hospital, Ankara, Turkey b Department of Radiology, Ankara Numune Education and Research Hospital, Ankara, Turkey c Department of Microbiology, Ankara Numune Education and Research Hospital, Ankara, Turkey d Department of Urology, Ankara Numune Education and Research Hospital, Ankara, Turkey e Department of Pathology, Ankara Numune Education and Research Hospital, Ankara, Turkey Received 18 October 2004; received in revised form 28 January 2005; accepted 24 February 2005 Corresponding Editor: Marguerite Neill, Pawtucket, USA KEYWORDS Summary Brucellosis; Brucella mellitensis; Background: Epididymoorchitis is the most frequent genitourinary complication of Brucella abortus; brucellosis. Epididymoorchitis; Methods: This prospective study was conducted between February 2001 and January Genitourinary 2004, prospectively. Male patients diagnosed with brucellosis were included in this infections study and evaluated for testicular involvement. Results: Epididymoorchitis was detected in 17 out of 134 (12.7%) male patients with brucellosis. Mean age of the patients was 36.9 Æ 7.1 years. Twelve patients (70.6%) had acute, four patients (23.5%) had subacute, and one patient (5.9%) had chronic brucellosis. The most common symptoms were scrotal pain (94%) and swelling (82%).
  • Binding of Androgen- and Estrogen-Like Flavonoids to Their Cognate (Non)Nuclear Receptors: a Comparison by Computational Prediction

    Binding of Androgen- and Estrogen-Like Flavonoids to Their Cognate (Non)Nuclear Receptors: a Comparison by Computational Prediction

    molecules Article Binding of Androgen- and Estrogen-Like Flavonoids to Their Cognate (Non)Nuclear Receptors: A Comparison by Computational Prediction Giulia D’Arrigo 1, Eleonora Gianquinto 1, Giulia Rossetti 2,3,4 , Gabriele Cruciani 5, Stefano Lorenzetti 6,* and Francesca Spyrakis 1,* 1 Department of Drug Science and Technology, University of Turin, Via Giuria 9, 10125 Turin, Italy; [email protected] (G.D.); [email protected] (E.G.) 2 Institute for Neuroscience and Medicine (INM-9) and Institute for Advanced Simulations (IAS-5) “Computational Biomedicine”, Forschungszentrum Jülich, 52425 Jülich, Germany 3 Jülich Supercomputing Center (JSC), Forschungszentrum Jülich, 52425 Jülich, Germany 4 Department of Neurology, RWTH, Aachen University, 52074 Aachen, Germany; [email protected] 5 Department of Chemistry, Biology and Biotechnology, University of Perugia, 06123 Perugia, Italy; [email protected] 6 Istituto Superiore di Sanità (ISS), Department of Food Safety, Nutrition and Veterinary Public Health, Viale Regina Elena 299, 00161 Rome, Italy * Correspondence: [email protected] (S.L.); [email protected] (F.S.) Abstract: Flavonoids are plant bioactives that are recognized as hormone-like polyphenols because of Citation: D’Arrigo, G.; Gianquinto, their similarity to the endogenous sex steroids 17β-estradiol and testosterone, and to their estrogen- E.; Rossetti, G.; Cruciani, G.; and androgen-like activity. Most efforts to verify flavonoid binding to nuclear receptors (NRs) and Lorenzetti, S.; Spyrakis, F. Binding of explain their action have been focused on ERα, while less attention has been paid to other nuclear Androgen- and Estrogen-Like and non-nuclear membrane androgen and estrogen receptors. Here, we investigate six flavonoids Flavonoids to Their Cognate (apigenin, genistein, luteolin, naringenin, quercetin, and resveratrol) that are widely present in fruits (Non)Nuclear Receptors: A and vegetables, and often used as replacement therapy in menopause.
  • Infertility in the Male Dog - a Diagnostic Approach [Infertilidade No Cão - Abordagem Clínica]

    Infertility in the Male Dog - a Diagnostic Approach [Infertilidade No Cão - Abordagem Clínica]

    Congresso de Ciências Veterinárias [Proceedings of the Veterinary Sciences Congress, 2002], SPCV, Oeiras, 10-12 Out., pp. 171-176 Animais de Companhia Infertility in the male dog - A diagnostic approach [Infertilidade no cão - Abordagem clínica] Stefano Romagnoli Introduction Infertility in the male dog can which has a normal libido and is able to mount can be due to lack of or incomplete ejaculation or to poor semen quality. Infertility due to inability to mount or to low libido may or may not be a reproductive issue (it is often an orthopedic or a behavioral problem) and will not be discussed here. Ejaculation problems Failure of or incomplete ejaculation may occur if the coital lock is not adequate because of fright or discomfort during mating or at semen collection. Ejaculation may sometimes occur retrogradely into the bladder if there is an incompetence of the internal urethral sphincter muscle Retrograde ejaculation - The ejaculatory process is coordinated by sympathetic and parasympathetic nervous activity, and is divided into seminal emission (the deposition of semen from the vasa deferentia and accessory sex glands into the prostatic urethra) and ejaculation (passage of semen through the uretra and outside through the external urethral orifice). During ejaculation the bladder neck contracts, thus playing an important role in preventing a retrograde flux of spermatozoa into the bladder. Vasa deferentia and bladder neck are primarily under the control of the sympathetic nervous system. Alfa-adrenoceptor stimulation causes contraction of the vas deferens, while beta- adrenoceptor stimulation mediates relaxation of the vas deferens. The use of alfa-adrenergic agonists increases seminal emission: for example, administration of xylazine (alfa-2 adrenoceptor agonist) in the dog causes increased contraction of vasa deferentia and decreased urethral pressure, thereby facilitating passage of spermatozoa into the bladder (not associated to ejaculation).
  • Diagnosis and Treatment of Infertility in Men: AUA/ASRM Guideline Part II Peter N

    Diagnosis and Treatment of Infertility in Men: AUA/ASRM Guideline Part II Peter N

    Diagnosis and treatment of infertility in men: AUA/ASRM guideline part II Peter N. Schlegel, M.D.,a Mark Sigman, M.D.,b Barbara Collura,c Christopher J. De Jonge, Ph.D, H.C.L.D.(A.B.B.),d Michael L. Eisenberg, M.D.,e Dolores J. Lamb, Ph.D., H.C.L.D.(A.B.B.),f John P. Mulhall, M.D.,g Craig Niederberger, M.D., F.A.C.S.,h Jay I. Sandlow, M.D.,i Rebecca Z. Sokol, M.D., M.P.H.,j Steven D. Spandorfer, M.D.,f Cigdem Tanrikut, M.D., F.A.C.S.,k Jonathan R. Treadwell, Ph.D.,l Jeffrey T. Oristaglio, Ph.D.,l and Armand Zini, M.D.m a New York Presbyterian Hospital-Weill Cornell Medical College; b Brown University; c RESOLVE; d University of Minnesota School of Medicine; e Stanford University School of Medicine; f Weill Cornell Medical College; g Memorial-Sloan Kettering Cancer Center; h Weill Cornell Medicine, University of Illinois-Chicago School of Medicine; i Medical College of Wisconsin; j University of Southern California School of Medicine; k Georgetown University School of Medicine; l ECRI; and m McGill University School of Medicine Purpose: The summary presented herein represents Part II of the two-part series dedicated to the Diagnosis and Treatment of Infertility in Men: AUA/ASRM Guideline. Part II outlines the appropriate management of the male in an infertile couple. Medical therapies, surgical techniques, as well as use of intrauterine insemination (IUI)/in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) are covered to allow for optimal patient management.
  • Don't Let Your Hair Down

    Don't Let Your Hair Down

    Hair ™ Patent N° WO 00/58347 PROCAPIL Don't let your Biotinyl-GHK, citrus and olive tree leaves hair down Function: Fights follicle ageing and protects against hair loss. Definition: Combination of a vitamin fortified matrikine™ (biotinyl-GHK) with apigenin (a flavonoid from citrus) and oleanolic acid from olive tree leaves. Properties: PROCAPILTM targets the main causes of alopecia: poor scalp micro-circulation, follicle ageing and follicle atrophy caused by dihydrotestosterone. Characteristics: Biotinyl-GHK stimulates cell metabolism, apigenin improves micro-circulation and oleanolic acid inhibits 5α-reductase. INCI name: Butylene Glycol – Water (Aqua) – PPG-26-Buteth-26 – PEG-40 Hydrogenated Castor Oil – Apigenin – Oleanolic Acid – Biotinoyl Tripeptide-1 Applications: Hair care products: shampoos, conditioners, leave-on, hair lotions, masks... Formulation: Fortifies Water soluble. Incorporate at 45°C in emulsions or at room temperature in gels. Rejuvenates Recommended use level: 1% to 2% Fights against hair loss Member of Croda International Plc Copyright© 2006 Sederma. All rights reserved. www.sederma.fr E-mail: [email protected] CLAIM SUBSTANTIATION April 2004 Stimulation of cell metabolism In vitro Examples of activated genes by PROCAPILTM Mitosis rate Gene Activity Activation Evaluation of root sheath keratinocytes after a Laminin binding protein Adhesion +146% 14-day culture of hair follicles. Biotiny-GHK (2 ppm) stimulates Ki-67 expression, indicating enhanced cell Acetyl CoA transferase Cell metabolism +137% proliferation. Cytokeratins 10 Differentiation +154% Gene expression Morphological observation PROCAPILTM promotes the expression of numerous control PROCAPILTM genes involved in tissue repair mechanisms (DNA-array on 3D SkinEthic® epidermis). Hair Root sheath Hair anchoring Hair follicles are incubated for 14 days with biotinyl-GHK Dermis / Root sheath (2 ppm).